References
- de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9
- Honeycutt AA, Segel JE, Zhuo X, et al. Medical costs of CKD in the Medicare population. J Am Soc Nephrol JASN 2013;24:1478-83
- United States Renal Data System. Medicare expenditures for persons with CKD 2016 annual data report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2016 https://www.usrds.org/2016/view/v1_06.aspx. Accessed August 2016
- Slabaugh SL, Curtis BH, Clore G, et al. Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US. J Med Econ 2015;18:106-12
- Laliberte F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manage Care Pharm JMCP 2009;15:312-22
- Ozieh MN, Dismuke CE, Lynch CP, et al. Medical care expenditures associated with chronic kidney disease in adults with diabetes: United States 2011. Diabetes Res Clin Prac 2015;109:185-90
- Nichols GA, Vupputuri S, Lau H. Medical care costs associated with progression of diabetic nephropathy. Diabetes Care 2011;34:2374-8
- Vupputuri S, Kimes TM, Calloway MO, et al. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complic 2014;28:10-16
- KDIGO National Guideline. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013;3:1-150
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
- Iglay K, Hannachi H, Joseph Howie P, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin 2016;32:1243-52
- Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009;32:2068-74
- Aagren M, Luo W. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. J Med Econ 2011;14:108-14
- Food and Drug Administration. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Washington, D.C, USA: U.S. Food and Drug Administration, 2016. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed August 2016
- Klompas M, Eggleston E, McVetta J, et al. Automated detection and classification of type 1 versus type 2 diabetes using electronic health record data. Diabetes Care 2013;36:914-21
- Zgibor JC, Orchard TJ, Saul M, et al. Developing and validating a diabetes database in a large health system. Diabetes Res Clin Prac 2007;75:313-9
- Wang V, Vilme H, Maciejewski ML, et al. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol 2016;36:319-30